Smokeless tobacco alternatives company Black Buffalo Inc announced on Tuesday that it has partnered with Sanova LLC, a New York-based scientific and regulatory consulting agency, to support its regulatory, compliance, and scientific research programmes.
Sanova has extensive experience helping nicotine manufacturers navigate complex regulatory frameworks, including the US Food and Drug Administration's (FDA) Premarket Tobacco Product Application (PMTA) and Modified Risk Tobacco Product (MRTP) pathways. Sanova's partnership with Black Buffalo includes helping guide the company through the final and most critical phases of FDA review, including substantive scientific review, a rigorous process that evaluates the health impact and overall safety profile of nicotine products intended for adult use.
Kellsi Booth, Black Buffalo's chief legal officer, said: "The Sanova team combines decades of FDA and industry insight with a forward-looking approach. Enlisting Sanova as a key partner represents our commitment to full regulatory transparency, scientific excellence, and responsible innovation within the nicotine space."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA